RESUMO
It is currently recommended that hydroxychloroquine (HCQ) be maintained during pregnancy in patients with systemic lupus erythematosus. Recent data suggest that this Toll-like receptor inhibitor may also reduce the recurrence rate of anti-SSA/Ro associated congenital heart block (CHB). This case report describes a unique situation in which a CHB-afflicted, HCQ-exposed pregnancy was electively terminated. The heart did not reveal any characteristic features of cardiotoxicity, providing further evidence supporting the safety of foetal exposure to HCQ.
Assuntos
Antirreumáticos/uso terapêutico , Bloqueio Cardíaco/congênito , Hidroxicloroquina/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Aborto Terapêutico , Adulto , Antirreumáticos/efeitos adversos , Autopsia , Cardiotoxicidade , Feminino , Coração Fetal/efeitos dos fármacos , Coração Fetal/patologia , Bloqueio Cardíaco/diagnóstico , Bloqueio Cardíaco/tratamento farmacológico , Bloqueio Cardíaco/imunologia , Bloqueio Cardíaco/patologia , Cardiopatias/induzido quimicamente , Cardiopatias/patologia , Humanos , Hidroxicloroquina/efeitos adversos , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/imunologia , Gravidez , Fatores de Risco , Resultado do TratamentoRESUMO
Cardiac involvement as a complication of severe acute respiratory syndrome coronavirus 2 infection in children is a relatively new entity. We present our initial experience managing children with coronavirus disease 2019-related acute myocardial injury. The 3 patients presented here represent a spectrum of the cardiac involvement noted in children with coronavirus disease 2019-related multisystem inflammatory syndrome, including myocarditis presenting as cardiogenic shock or heart failure with biventricular dysfunction, valvulitis, coronary artery changes, and pericardial effusion.